Epigral Posts Q1FY26 Revenue of Rs 6.15 Bn; PAT Surges to Rs 1.60 Bn

04 Aug 2025 CW Team

Epigral, India’s integrated chemical major, reported revenue of Rs 6.15 billion for the quarter ended June 30, 2025, compared to Rs 6.54 billion in Q1FY25—a 6 per cent year-on-year decline, driven by softer volumes and lower realisations. Despite this, the company maintained a stable EBITDA margin of 27 per cent, supported by efficiency gains and an improved product mix. EBITDA stood at Rs 1.63 billion, a 7 per cent dip over the previous year.

Profit after tax (PAT) for the quarter stood at Rs 1.60 billion, benefiting from a Rs 810 million decrease in deferred tax liability. Excluding this, PAT was Rs 790 million versus Rs 860 million in the same quarter last year. Plant utilisation stood at 73 per cent during the quarter. The company’s return on capital employed (ROCE) improved to 24 per cent, up from 21 per cent a year ago, driven by better earnings, while Net Debt/EBITDA fell to 0.6x from 1.6x, reflecting stronger operating performance and deleveraging.

Revenue contribution from the Derivatives and Specialty Chemicals segment reached 50 per cent, and management expects this to rise further in coming quarters. Ongoing capex for CPVC and Epichlorohydrin capacity expansion remains on track in terms of budget and timeline. Additionally, the company plans to announce new investments for a remaining land parcel within its integrated complex.

Commenting on the performance, Maulik Patel, Chairman and Managing Director, said, “We expect H2FY26 to be stronger than H1FY26. Our focus on new chemistry aligned with import substitution will support high growth and strong ROCE. We continue to strengthen our integrated operations while pursuing scalable and profitable growth.”

Infrastructure Urban

10 Mar 2026

ABB to Invest Rs 6.25 Billion to Expand India Manufacturing

ABB recently announced plans to invest approximately Rs 6.25 billion ($75 million) in India during 2026 to expand its manufacturing footprint and research and development capabilities. The investment follows more than $35 million spent in 2025 and reflects the company’s continued focus on strengthening its ‘local-for-local’ strategy in the country.The investment will support ABB’s Electrification, Motion and Automation businesses and expand manufacturing capacity for infrastructure sectors such as renewable energy, metro rail, data centres and industrial applications. Approximately 300..

Six WOLFF Cranes Handle 60,000 m³ Concrete for German Hospital

Six WOLFF tower cranes are playing a key role in constructing a new hospital complex in Memmingen, Germany, supporting large-scale material handling for the project. The facility is being built on a 7.7-hectare site and will feature six floors, around 480 beds and a gross floor area exceeding 75,000 sq m.Building shell works began recently in February 2025. One WOLFF 6531.12 Cross crane supported early site preparation before being dismantled in autumn 2025, while five remaining cranes continue operations. Over an average deployment period of 16 months, the cranes are expected to move approxim..

REC Funds Rs 115.6 Million CSR Support for Bihar Eye Hospital

REC recently committed Rs 115.6 million under its Corporate Social Responsibility (CSR) programme for the procurement of clinical and non-clinical equipment at Sankara Eye Hospital in Saharsa, Bihar. The initiative aims to strengthen healthcare infrastructure and improve access to specialised eye care services in the region.A Memorandum of Agreement (MoA) was recently signed between Pradeep Fellows, Executive Director (CSR), REC Limited, and Wg Cdr V. Shankar (Retd), Trustee and Executive Director of Sankara Eye Hospital, at the REC office in the SCOPE Complex, New Delhi.The support is expecte..